Xenon files azetukalner NDA; X-NOVA2 topline set for Q1 2027
Xenon Pharmaceuticals says it has filed an NDA for azetukalner as an adjunctive focal seizure treatment and expects X-NOVA2 topline data in Q1 2027, without further timing details.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.